IP Verse

Tauroursodeoxycholic Acid (Tudca) For Use In The Treatment Of Neurodegenerative Disorders - EP3016654

The patent EP3016654 was granted to Bruschettini on Sep 5, 2018. The application was originally filed on Jul 1, 2013 under application number EP13747521A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3016654

BRUSCHETTINI
Application Number
EP13747521A
Filing Date
Jul 1, 2013
Status
Granted And Under Opposition
Aug 3, 2018
Grant Date
Sep 5, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMMELBURGJun 4, 2019FISH & RICHARDSON PCADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP2422787
INTERNATIONAL-SEARCH-REPORTWO2004096123
INTERNATIONAL-SEARCH-REPORTWO2006050165
INTERNATIONAL-SEARCH-REPORTWO2006086452
OPPOSITIONEP2422787
OPPOSITIONUS2011142799
OPPOSITIONWO2004096123
OPPOSITIONWO2006050165
OPPOSITIONWO2006086452

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- AXCAN PHARMA US INC., "URSO (ursodiol) Tablets, 250 mg, Treatment of Patients With All Stages of Primary Biliary Cirrhosis", Medical Officer's Review; NDA 20-675, (19960326), XP055607275-
OPPOSITION- DUAN W-M et al., "Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease", Cell Transplantation, (20020101), vol. 11, no. 3, pages 195 - 205, XP009064566-
OPPOSITION- "Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis (TUDCA-ALS)", CLINICAL TRIALS.GOV, (20120323), URL: http://www.clinicaltrials.gov/ct2/show/NCT00877604?term=tudca&rank=1, XP002714173-
OPPOSITION- MAURER M, "Amyotrophic Lateral Sclerosis: An Introduction to Treatment and Trials", Amyotrophic Lateral Sclerosis, ISBN 978-953-307-806-9, (20120120), pages 1 - 40, URL: https://www.intechopen.com/books/amyotrophic-lateral-sclerosis/amyotrophic-lateral-sclerosis-an-introduction-to-treatment-and-trials, XP055607277-
OPPOSITION- SUNG JJ et al., "Tauroursodeoxycholic acid (TUDCA), a bile acid, inhibits GSNO- induced apoptosis by modulating reactive oxygen species (ROS) production in motor neuronal cells expressing mutant Cu/Zn superoxide dismutase (SOD1", THEME 4 In vitro Experimental Models, Amyotrophic Lateral Sclerosis, (20090710), vol. 6, no. P81, pages 109 - 110-
OPPOSITION- TAUB, K, "TUDCA: Tauroursodeoxycholic Acid", Standford.edu, (20041114), pages 1 - 2, URL: URL:http://www.stanford.edu/group/hopes/cgi-bin/wordpress/2010/06/tudca-tauroursodeoxycholic-acid, XP002714174-
OPPOSITION- KEENE , CD et al., "Tauroursodeoxycholic acid, a bile acid is neuroprotective in a transgenic animal model of Huntington's disease", PNAS, (20020806), vol. 99, no. 16, doi:10.1073/pnas.162362299, pages 10671 - 10676, XP008038001
OPPOSITION- PARRY GJ et al., "Safety, tolerability, and cerebrospinal fluid penetration of Ursodeoxycholic Acid in patients with Amyotrophic Lateral Sclerosis", Clinical Neuropharmacology, (20100100), vol. 33, no. 1, pages 17 - 21, XP055607274
OPPOSITION- ELIA AE et al., "Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis", EUROPEAN JOURNAL OF NEUROLOGY, (20150209), vol. 23, no. 1, pages 42 - 52, XP055351410
OPPOSITION- CASTRO RE et al., "The bile acid Tauroursodeoxycholic Acid modulates phosphorylation and translocation of Bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons", The Journal of Pharmacology and Experimental Therapeutics, (20040609), vol. 311, no. 2, doi:10.1124/jpet.104.070532, pages 845 - 852, XP055082120
OPPOSITION- MIN J-H et al., "Oral solubilized Ursodeoxycholic acid therapy in Amyotrophic Lateral Sclerosis: A randomized cross-over trial", The Journal of Korean Medical Science, (20120127), vol. 27, no. 2, doi:10.3346/jkms.2012.27.2.200, XP055434430

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents